FDA seeks support for reorganization of cancer programs, but debate continues.
In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
Duke recruits Judd Moul as chief of urology.
Foundation offers funds for mesothelioma research.
Other NCI funding opportunities listed.
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”